JACC Journals

09/02/2026

In this author interview, lead author Dr. Troels Højsgaard Jørgensen and senior author Dr. Ole De Backer join Executive Associate Editor Dr. Aakriti Gupta to discuss the NOTION-4 trial, presented as a HOTLINE at 2026 this past weekend.

The randomized trial tested whether 3 months of direct oral anticoagulant therapy after , followed by lifelong single antiplatelet therapy, could reduce subclinical leaflet thrombosis compared with single antiplatelet therapy alone.

📄: https://bit.ly/45TsrqR
📽️: https://youtu.be/wUkJaN13heE?si=lGch5Az3GcakCrAm

In this JACC author interview, lead author Dr. Troels Højsgaard Jør...

09/01/2026

Environmental exposures such as air pollution, wildfire smoke, and extreme heat are increasingly recognized as important contributors to cardiovascular disease, even at levels once considered safe. The latest issue examines the evidence linking these exposures to cardiovascular risk and explores opportunities for prevention at both the individual and population levels.

Read the full issue: https://bit.ly/4yceNLk

09/01/2026

In a new edition of ACC's Cardiology Hour, Dr. Valentin Fuster is joined by expert panelists Drs. Biykem Bozkurt, Paulus Kirchhof, Mohamad Alkhouli, and Michael Borger in a lively discussion on top LBCTs released during , such as NOTION-4, SINGLE-AF, and more!

📽️:

ESC Congress 2026 featured 58 Hot Line clinical trial presentations...

09/01/2026

In this interview recorded at 2026, Associate Editor Jason Wasfy, MD, MPhil, sits down with Steven E. Nissen, MD, to discuss new findings on lipoprotein(a), oxidized phospholipids, and the Phase 2 lepodisiran program.

Learn how these results may help researchers better understand the mechanisms of cardiovascular risk and guide the development of future therapies: https://bit.ly/3UiDsQ1 https://youtu.be/qAXs7Lu5KcQ?si=6JLbBjh3-9f7vSrY

In this JACC interview recorded at ESC Congress 2026, JACC Associat...

08/31/2026

In this exploratory randomized trial extension, no statistically significant difference in all-cause mortality was detected between and CABG. The broad 95% CI does not exclude a clinically meaningful advantage of either strategy. https://bit.ly/4y7OMgr

08/31/2026

Patients with Loeys-Dietz syndrome may develop acute type A aortic dissection despite guideline-concordant surveillance and aortic dimensions below current surgical thresholds, underscoring the need for improved individualized risk stratification beyond maximal aortic diameter. Lifelong multidisciplinary clinical and imaging surveillance after complex aortic root reconstruction remains essential, as delayed vascular and graft-related complications, including coronary interposition graft thrombosis, may occur despite initially successful surgical management. https://bit.ly/4ycncP3

08/31/2026

Lepodisiran produced sustained reductions in OxPL-apoB and OxPL-apo(a) levels that correlated with Lp(a) lowering. These findings provide additional biological rationale for the ongoing lepodisiran phase 3 cardiovascular outcomes trial, but do not establish clinical benefit. https://bit.ly/3UiDsQ1

08/31/2026

In patients with , CSP-CRT was noninferior to BiV-CRT in reducing LVESV and both treatment modalities provided similar and excellent improvements in , QRS duration, heart failure symptoms, and functional capacity. https://bit.ly/4cLejUg

08/31/2026

Stentless percutaneous coronary intervention (PCI) with drug-coated balloon was frequently used in patients undergoing PCI for bypass graft lesions in Japan and was not associated with a significant difference in 1-year clinical outcomes compared with contemporary drug-eluting stent-based PCI strategies.

Get the details: https://bit.ly/4xtkGUP

08/31/2026

🔥 What had everyone talking on Day 2 of 2026? Deputy Editor John A. Spertus, MD, MPH, FACC, and JACC Associate Editor Marc P. Bonaca, MD, MPH, FACC, share top takeaways from Munich.

▶️ Watch now: https://bit.ly/4y3qAMa

What stood out on day 2 of ESC Congress 2026? JACC Deputy Editor Jo...